Skip to main content
Clinical Trials/CTRI/2024/03/064773
CTRI/2024/03/064773RecruitingNot Applicable

Evaluation of Intense Pulsed Light Therapy & Conservative Treatment in Meibomian Gland Disease- A Prospective Observational Comparative Study

Tulika Srivastava1 site in 1 country120 target enrollmentStarted: April 1, 2024Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
120
Locations
1
Primary Endpoint
Improvement of meibomian gland function

Study Overview

Brief Summary

The objective is to assess and compare the efficacy of Intense Pulsed Light therapy and conservative management in improving clinical outcomes for MGD in different patients, focusing on symptom relief, tear film stability, and overall ocular surface health

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18.00 Year(s) to 99.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Age 18 years and above patients diagnosed with MGD patients who are known case of MGD.

Exclusion Criteria

  • age below 18 years acute ocular infection or inflammation.

Outcomes

Primary Outcomes

Improvement of meibomian gland function

Time Frame: 4weeks 12weeks 24weeks

Secondary Outcomes

  • Improvement in symptoms(1 month 3 months 6 months)

Investigators

Sponsor
Tulika Srivastava
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Tulika Srivastava

Centre for Sight Eye Institute Dwarka

Study Sites (1)

Loading locations...

Similar Trials